Please Wait

Applying Filters...

Global API micronization market set to surge 49% by 2030, led by specialized industry pioneers

Data Compilation
#PharmaFlow

Pipeline Prospector August 2025: Novo’s Wegovy approved for MASH, Tonix Pharma’s fibromyalgia drug okayed

Stock Recap
#PipelineProspector

PIPERACILLIN; TAZOBACTAM-1

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 17 USDMF, 10 JDMF, 1 EU WC, 2 KDMF, 8 NDC API, 9 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

38 Drugs in Development

38 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

233 FDF Dossiers, 60 FDA Orange Book, 101 Europe, 12 South Africa, 60 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 40MG BASE/ML;EQ 5MG BASE/ML, INJECTABLE;INJECTION - EQ 4GM BASE/100ML;EQ 500MG BASE/100ML, INJECTABLE;INJECTION - EQ 60MG BASE/ML;EQ 7.5MG BASE/ML

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 1 Pfanstiehl, 5 Kirsch Pharma, 3 Actylis, 1 Pluviaendo, 4 Roquette

EXCIPIENTS BY APPLICATIONS

10 Parenteral, 2 Thickeners and Stabilizers, 2 API Stability Enhancers, 2 Fillers, Diluents & Binders

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 44 News #PharmaBuzz

GLOBAL SALES INFORMATION

23 US Medicaid Prescriptions, 17 Regulatory FDF Prices, 12 Annual Reports

MARKET PLACE

15 APIs, 5 FDF Dossiers

PATENTS & EXCLUSIVITIES

28 US Patents, 1 US Exclusivities, 6 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 Others

4 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
27/09/2025	Jiangxi Fushine Pharmaceutical Co. Ltd	China	Sangjin Trading Co., Ltd.	20190621-210-J-367	Tazobactam	2019-06-21	Jiangxi Fushine Pharmaceutical Co., Ltd.	China	No. 2, Yuli Industrial Zone, Changjiang District, Jingdezhen City, Jiangxi Province, China
27/09/2025	Qilu Tianhe Pharmaceutical Co., Ltd.	China	MSD Korea Co., Ltd.	20200810-210-J-449	Tazobactam sodium	2020-08-10	Shandong Anxin Pharmaceutical Co., Ltd. (formerly Qilu Tianhe Pharmaceutical. Co. Ltd)	China	No. 849, Dongjia Town, Licheng District, 250105 Jinan, Shandong Province, PR of China

Contact us
to update this info

PIPERACILLIN; TAZOBACTAM-1

PIPERACILLIN; TAZOBACTAM-1

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

35 API Suppliers

17 USDMF

10 JDMF

1 EU WC

2 KDMF

8 NDC API

9 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

38 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

233 FDF Dossiers

60 FDA Orange Book

101 Europe

12 South Africa

60 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 40MG BASE/ML;EQ 5MG BASE/ML

INJECTABLE;INJECTION - EQ 4GM BASE/100ML;EQ 500MG BASE/100ML

INJECTABLE;INJECTION - EQ 60MG BASE/ML;EQ 7.5MG BASE/ML

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

1 Pfanstiehl

5 Kirsch Pharma

3 Actylis

1 Pluviaendo

4 Roquette

EXCIPIENTS BY APPLICATIONS

10 Parenteral

2 Thickeners and Stabilizers

2 API Stability Enhancers

2 Fillers, Diluents & Binders

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

44 News #PharmaBuzz

GLOBAL SALES INFORMATION

23 US Medicaid Prescriptions

17 Regulatory FDF Prices

12 Annual Reports

MARKET PLACE

15 APIs

5 FDF Dossiers

PATENTS & EXCLUSIVITIES

28 US Patents

1 US Exclusivities

6 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 Others

Filters

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons